MiNK Therapeutics INKT Institutional Ownership

MiNK Therapeutics, Inc. (NASDAQ:INKT) has 28 institutional investors that have filed 13F reports for the period ending June 2026.

• They owned 4.1% of outstanding stock in June 2026, up from 2.6% the prior quarter.
• Their total shares held in INKT increased 61.57% quarter over quarter, and separately, investors owning MiNK Therapeutics increased 47.37% from a year ago.
• Among the 28 funds, 14 bought more MiNK Therapeutics shares, 3 sold down, and 11 held their ground.
• The aggregate institutional position in MiNK Therapeutics amounted to 204.45K shares as of June 2026, up by 77.91K shares quarter on quarter, and up 142.55K shares year over year.
• VANGUARD CAPITAL MANAGEMENT LLC is the top holder of MiNK Therapeutics as of June 30, 2026, with 68.66K shares representing 1.37% of outstanding stock.
• The largest buyers of MiNK Therapeutics for the quarter ending June 2026 were DnB Asset Management AS (55.14K), CITADEL ADVISORS LLC (15.44K), VANGUARD CAPITAL MANAGEMENT LLC (9.3K), BlackRock, Inc. (7.18K), Us Bancorp De (2.0K).
• Leading sellers of MiNK Therapeutics shares for the quarter ending June 2026 were UBS Group AG (10.32K), GEODE CAPITAL MANAGEMENT, LLC (1.77K), BNP PARIBAS FINANCIAL MARKETS (3).
• Per Business Quant, the top 10 investors in INKT for the quarter ending June 2026 include VANGUARD CAPITAL MANAGEMENT LLC (68.66K), DnB Asset Management AS (55.14K), Longbow Finance SA (16.67K), GEODE CAPITAL MANAGEMENT, LLC (15.57K), CITADEL ADVISORS LLC (15.44K), BlackRock, Inc. (13.38K), VANGUARD FIDUCIARY TRUST CO (8.29K), UBS Group AG (4.88K), Steward Partners Investment Advisory, LLC (2.0K), Us Bancorp De (2.0K).